A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Liver Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00563095|
Recruitment Status : Unknown
Verified July 2010 by Hospital Authority, Hong Kong.
Recruitment status was: Recruiting
First Posted : November 26, 2007
Last Update Posted : July 7, 2010
Primary: To compare the efficacy of TACE and TAIE.
Secondary: To compare the side effects of TACE and TAIE.
The outcome measurements include survival benefit and tumour regression induced by the two therapies.
|Condition or disease||Intervention/treatment||Phase|
|Carcinoma, Hepatocellular||Procedure: Transcatheter Arterial Chemoembolization (TACE) Procedure: Transcatheter Arterial Pegylated Interferon Embolization (TAIE)||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Hepatocellular Carcinoma|
|Study Start Date :||March 2004|
|Estimated Study Completion Date :||December 2008|
- regression of tumour size [ Time Frame: assessment every 6 months ]
- side effects [ Time Frame: every treatment given every 8 - 12 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00563095
|Contact: Man Fung Yuen, Prof||(852) 2855 firstname.lastname@example.org|
|Queen Mary Hospital||Recruiting|
|Hong Kong, China|
|Sub-Investigator: Ching Lung Lai, Prof|
|Sub-Investigator: Clara Ooi, Prof|
|Principal Investigator:||Man Fung Yuen, Prof||Department of Medicine, Queen Mary Hospital/ The University of Hong Kong|